Age (years)
|
45.3 ± 7.7
|
59.2 ± 3.9
|
0.247a
|
Gender
| | |
0.545b
|
Male
|
1 (16.7%)
|
2 (40.0%)
| |
Female
|
5 (83.3%)
|
3 (60.0%)
| |
Time from symptoms and signs to treatment (days)
|
3.5 ± 1.1
|
10.8 ± 5.5
|
0.329a
|
Performance status (ECOG)
| | |
0.455b
|
< 2
|
2 (33.3%)
|
0 (0.0%)
| |
≥ 2
|
4 (66.7%)
|
5 (100.0%)
| |
Lactate dehydrogenase (IU/l)
|
300.8 ± 38.4
|
433.2 ± 149.6
|
0.792a
|
Extra-nodal involvement >1 site
| | |
0.242b
|
Yes
|
2 (33.3%)
|
4 (80.0%)
| |
No
|
4 (66.7%)
|
1 (20.0%)
| |
Stage
| | |
0.545b
|
1
|
3 (50.0%)
|
1 (20.0%)
| |
4
|
3 (50.0%)
|
4 (80.0%)
| |
International Prognostic Index score
| | |
0.545b
|
Low/low-intermediate
|
3 (50.0%)
|
1 (20.0%)
| |
High/high-intermediate
|
3 (50.0%)
|
4 (80.0%)
| |
Neurological deficit recovery
| | |
0.015b
|
Complete
|
6 (100.0%)
|
1 (20.0%)
| |
Partial
|
0 (0.0%)
|
4 (80.0%)
| |
Overall survival (months)
|
48.6 ± 13.7
|
17.8 ± 3.4
|
0.177a
|